Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

Ceftibuten-ledaborbactam etzadroxil is a cephalosporin-boronate β-lactamase inhibitor prodrug combination under development as an oral treatment for complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales producing serine β-lactamases (Ambler class A, C, and D). In...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlowsky, James A., Wise, Mark G., Hackel, Meredith A., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664860/
https://www.ncbi.nlm.nih.gov/pubmed/36286518
http://dx.doi.org/10.1128/aac.00934-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664860/
https://www.ncbi.nlm.nih.gov/pubmed/36286518
http://dx.doi.org/10.1128/aac.00934-22

Ejemplares similares